• レポートコード:MRC2-11QY08781 • 出版社/出版日:QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態:英文、PDF、186ページ • 納品方法:Eメール(納期:2~3日) • 産業分類:医療、製薬 |
Single User | ¥585,000 (USD3,900) | ▷ お問い合わせ |
Multi User | ¥877,500 (USD5,850) | ▷ お問い合わせ |
Enterprise License | ¥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料はPDE阻害剤のグローバル市場について調査・分析したレポートです。種類別(PDE5、PDE4、バイアグラ、シアリス、レビトラ、その他)市場規模、用途別(泌尿生殖器、心血管疾患、皮膚疾患、呼吸器疾患、統合失調症、アルツハイマー病、ハンチントン病、その他)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別PDE阻害剤の競争状況、市場シェア ・世界のPDE阻害剤市場:種類別市場規模 2015年-2020年(PDE5、PDE4、バイアグラ、シアリス、レビトラ、その他) ・世界のPDE阻害剤市場:種類別市場規模予測 2021年-2026年(PDE5、PDE4、バイアグラ、シアリス、レビトラ、その他) ・世界のPDE阻害剤市場:用途別市場規模 2015年-2020年(泌尿生殖器、心血管疾患、皮膚疾患、呼吸器疾患、統合失調症、アルツハイマー病、ハンチントン病、その他) ・世界のPDE阻害剤市場:用途別市場規模予測 2021年-2026年(泌尿生殖器、心血管疾患、皮膚疾患、呼吸器疾患、統合失調症、アルツハイマー病、ハンチントン病、その他) ・北米のPDE阻害剤市場分析:米国、カナダ ・ヨーロッパのPDE阻害剤市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのPDE阻害剤市場分析:日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のPDE阻害剤市場分析:メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのPDE阻害剤市場分析:トルコ、サウジアラビア、UAE等 ・企業情報(企業概要、製品概要、販売量、企業動向) - 掲載企業(変更可能性あり):Hanmi Science Holding、Boehringer Ingelheim、Takeda Pharmaceuticals、AstraZeneca、Bayer、Celgene、Eli Lilly、Pfizer、BioCrea、Dart NeuroScience、Carinopharm、CTC Bio、FORUM Pharmaceuticals、Intra-Cellular Therapies、Omeros Corporation、Medimetriks Pharmaceuticals、NuSirt Biopharma、Palobiopharma、Roivant Sciences、Sagene Pharmaceuticals、Tetra Discovery Partners、Tritech Biopharm、Otsuka、Chiesi Farmaceutici、Verona Pharma ・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global PDE Inhibitors Market
The global PDE Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global PDE Inhibitors Scope and Market Size
PDE Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global PDE Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the PDE Inhibitors market is segmented into
PDE5
PDE4
Viagra
Cialis
Levitra
Others
Segment by Application, the PDE Inhibitors market is segmented into
Genitourinary
Cardiovascular Diseases
Dermatological Disorders
Respiratory Diseases
Schizophrenia
Alzheimer’S Disease
Huntington’S Disease
Others
Regional and Country-level Analysis
The PDE Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the PDE Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and PDE Inhibitors Market Share Analysis
PDE Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in PDE Inhibitors business, the date to enter into the PDE Inhibitors market, PDE Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Hanmi Science Holding
Boehringer Ingelheim
Takeda Pharmaceuticals
AstraZeneca
Bayer
Celgene
Eli Lilly
Pfizer
BioCrea
Dart NeuroScience
Carinopharm
CTC Bio
FORUM Pharmaceuticals
Intra-Cellular Therapies
Omeros Corporation
Medimetriks Pharmaceuticals
NuSirt Biopharma
Palobiopharma
Roivant Sciences
Sagene Pharmaceuticals
Tetra Discovery Partners
Tritech Biopharm
Otsuka
Chiesi Farmaceutici
Verona Pharma
1 Study Coverage
1.1 PDE Inhibitors Product Introduction
1.2 Market Segments
1.3 Key PDE Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global PDE Inhibitors Market Size Growth Rate by Type
1.4.2 PDE5
1.4.3 PDE4
1.4.4 Viagra
1.4.5 Cialis
1.4.6 Levitra
1.4.7 Others
1.5 Market by Application
1.5.1 Global PDE Inhibitors Market Size Growth Rate by Application
1.5.2 Genitourinary
1.5.3 Cardiovascular Diseases
1.5.4 Dermatological Disorders
1.5.5 Respiratory Diseases
1.5.6 Schizophrenia
1.5.7 Alzheimer’S Disease
1.5.8 Huntington’S Disease
1.5.9 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global PDE Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global PDE Inhibitors Revenue 2015-2026
2.1.2 Global PDE Inhibitors Sales 2015-2026
2.2 Global PDE Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global PDE Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global PDE Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global PDE Inhibitors Competitor Landscape by Players
3.1 PDE Inhibitors Sales by Manufacturers
3.1.1 PDE Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 PDE Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 PDE Inhibitors Revenue by Manufacturers
3.2.1 PDE Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 PDE Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global PDE Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by PDE Inhibitors Revenue in 2019
3.2.5 Global PDE Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 PDE Inhibitors Price by Manufacturers
3.4 PDE Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 PDE Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers PDE Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into PDE Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global PDE Inhibitors Market Size by Type (2015-2020)
4.1.1 Global PDE Inhibitors Sales by Type (2015-2020)
4.1.2 Global PDE Inhibitors Revenue by Type (2015-2020)
4.1.3 PDE Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global PDE Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global PDE Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global PDE Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 PDE Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global PDE Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global PDE Inhibitors Market Size by Application (2015-2020)
5.1.1 Global PDE Inhibitors Sales by Application (2015-2020)
5.1.2 Global PDE Inhibitors Revenue by Application (2015-2020)
5.1.3 PDE Inhibitors Price by Application (2015-2020)
5.2 PDE Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global PDE Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global PDE Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global PDE Inhibitors Price Forecast by Application (2021-2026)
6 North America
6.1 North America PDE Inhibitors by Country
6.1.1 North America PDE Inhibitors Sales by Country
6.1.2 North America PDE Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America PDE Inhibitors Market Facts & Figures by Type
6.3 North America PDE Inhibitors Market Facts & Figures by Application
7 Europe
7.1 Europe PDE Inhibitors by Country
7.1.1 Europe PDE Inhibitors Sales by Country
7.1.2 Europe PDE Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe PDE Inhibitors Market Facts & Figures by Type
7.3 Europe PDE Inhibitors Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific PDE Inhibitors by Region
8.1.1 Asia Pacific PDE Inhibitors Sales by Region
8.1.2 Asia Pacific PDE Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific PDE Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific PDE Inhibitors Market Facts & Figures by Application
9 Latin America
9.1 Latin America PDE Inhibitors by Country
9.1.1 Latin America PDE Inhibitors Sales by Country
9.1.2 Latin America PDE Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America PDE Inhibitors Market Facts & Figures by Type
9.3 Central & South America PDE Inhibitors Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa PDE Inhibitors by Country
10.1.1 Middle East and Africa PDE Inhibitors Sales by Country
10.1.2 Middle East and Africa PDE Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 UAE
10.2 Middle East and Africa PDE Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa PDE Inhibitors Market Facts & Figures by Application
11 Company Profiles
11.1 Hanmi Science Holding
11.1.1 Hanmi Science Holding Corporation Information
11.1.2 Hanmi Science Holding Description and Business Overview
11.1.3 Hanmi Science Holding Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Hanmi Science Holding PDE Inhibitors Products Offered
11.1.5 Hanmi Science Holding Related Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Corporation Information
11.2.2 Boehringer Ingelheim Description and Business Overview
11.2.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Boehringer Ingelheim PDE Inhibitors Products Offered
11.2.5 Boehringer Ingelheim Related Developments
11.3 Takeda Pharmaceuticals
11.3.1 Takeda Pharmaceuticals Corporation Information
11.3.2 Takeda Pharmaceuticals Description and Business Overview
11.3.3 Takeda Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Takeda Pharmaceuticals PDE Inhibitors Products Offered
11.3.5 Takeda Pharmaceuticals Related Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Description and Business Overview
11.4.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.4.4 AstraZeneca PDE Inhibitors Products Offered
11.4.5 AstraZeneca Related Developments
11.5 Bayer
11.5.1 Bayer Corporation Information
11.5.2 Bayer Description and Business Overview
11.5.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bayer PDE Inhibitors Products Offered
11.5.5 Bayer Related Developments
11.6 Celgene
11.6.1 Celgene Corporation Information
11.6.2 Celgene Description and Business Overview
11.6.3 Celgene Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Celgene PDE Inhibitors Products Offered
11.6.5 Celgene Related Developments
11.7 Eli Lilly
11.7.1 Eli Lilly Corporation Information
11.7.2 Eli Lilly Description and Business Overview
11.7.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Eli Lilly PDE Inhibitors Products Offered
11.7.5 Eli Lilly Related Developments
11.8 Pfizer
11.8.1 Pfizer Corporation Information
11.8.2 Pfizer Description and Business Overview
11.8.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Pfizer PDE Inhibitors Products Offered
11.8.5 Pfizer Related Developments
11.9 BioCrea
11.9.1 BioCrea Corporation Information
11.9.2 BioCrea Description and Business Overview
11.9.3 BioCrea Sales, Revenue and Gross Margin (2015-2020)
11.9.4 BioCrea PDE Inhibitors Products Offered
11.9.5 BioCrea Related Developments
11.10 Dart NeuroScience
11.10.1 Dart NeuroScience Corporation Information
11.10.2 Dart NeuroScience Description and Business Overview
11.10.3 Dart NeuroScience Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Dart NeuroScience PDE Inhibitors Products Offered
11.10.5 Dart NeuroScience Related Developments
11.1 Hanmi Science Holding
11.1.1 Hanmi Science Holding Corporation Information
11.1.2 Hanmi Science Holding Description and Business Overview
11.1.3 Hanmi Science Holding Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Hanmi Science Holding PDE Inhibitors Products Offered
11.1.5 Hanmi Science Holding Related Developments
11.12 CTC Bio
11.12.1 CTC Bio Corporation Information
11.12.2 CTC Bio Description and Business Overview
11.12.3 CTC Bio Sales, Revenue and Gross Margin (2015-2020)
11.12.4 CTC Bio Products Offered
11.12.5 CTC Bio Related Developments
11.13 FORUM Pharmaceuticals
11.13.1 FORUM Pharmaceuticals Corporation Information
11.13.2 FORUM Pharmaceuticals Description and Business Overview
11.13.3 FORUM Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.13.4 FORUM Pharmaceuticals Products Offered
11.13.5 FORUM Pharmaceuticals Related Developments
11.14 Intra-Cellular Therapies
11.14.1 Intra-Cellular Therapies Corporation Information
11.14.2 Intra-Cellular Therapies Description and Business Overview
11.14.3 Intra-Cellular Therapies Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Intra-Cellular Therapies Products Offered
11.14.5 Intra-Cellular Therapies Related Developments
11.15 Omeros Corporation
11.15.1 Omeros Corporation Corporation Information
11.15.2 Omeros Corporation Description and Business Overview
11.15.3 Omeros Corporation Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Omeros Corporation Products Offered
11.15.5 Omeros Corporation Related Developments
11.16 Medimetriks Pharmaceuticals
11.16.1 Medimetriks Pharmaceuticals Corporation Information
11.16.2 Medimetriks Pharmaceuticals Description and Business Overview
11.16.3 Medimetriks Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Medimetriks Pharmaceuticals Products Offered
11.16.5 Medimetriks Pharmaceuticals Related Developments
11.17 NuSirt Biopharma
11.17.1 NuSirt Biopharma Corporation Information
11.17.2 NuSirt Biopharma Description and Business Overview
11.17.3 NuSirt Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.17.4 NuSirt Biopharma Products Offered
11.17.5 NuSirt Biopharma Related Developments
11.18 Palobiopharma
11.18.1 Palobiopharma Corporation Information
11.18.2 Palobiopharma Description and Business Overview
11.18.3 Palobiopharma Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Palobiopharma Products Offered
11.18.5 Palobiopharma Related Developments
11.19 Roivant Sciences
11.19.1 Roivant Sciences Corporation Information
11.19.2 Roivant Sciences Description and Business Overview
11.19.3 Roivant Sciences Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Roivant Sciences Products Offered
11.19.5 Roivant Sciences Related Developments
11.20 Sagene Pharmaceuticals
11.20.1 Sagene Pharmaceuticals Corporation Information
11.20.2 Sagene Pharmaceuticals Description and Business Overview
11.20.3 Sagene Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Sagene Pharmaceuticals Products Offered
11.20.5 Sagene Pharmaceuticals Related Developments
11.21 Tetra Discovery Partners
11.21.1 Tetra Discovery Partners Corporation Information
11.21.2 Tetra Discovery Partners Description and Business Overview
11.21.3 Tetra Discovery Partners Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Tetra Discovery Partners Products Offered
11.21.5 Tetra Discovery Partners Related Developments
11.22 Tritech Biopharm
11.22.1 Tritech Biopharm Corporation Information
11.22.2 Tritech Biopharm Description and Business Overview
11.22.3 Tritech Biopharm Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Tritech Biopharm Products Offered
11.22.5 Tritech Biopharm Related Developments
11.23 Otsuka
11.23.1 Otsuka Corporation Information
11.23.2 Otsuka Description and Business Overview
11.23.3 Otsuka Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Otsuka Products Offered
11.23.5 Otsuka Related Developments
11.24 Chiesi Farmaceutici
11.24.1 Chiesi Farmaceutici Corporation Information
11.24.2 Chiesi Farmaceutici Description and Business Overview
11.24.3 Chiesi Farmaceutici Sales, Revenue and Gross Margin (2015-2020)
11.24.4 Chiesi Farmaceutici Products Offered
11.24.5 Chiesi Farmaceutici Related Developments
11.25 Verona Pharma
11.25.1 Verona Pharma Corporation Information
11.25.2 Verona Pharma Description and Business Overview
11.25.3 Verona Pharma Sales, Revenue and Gross Margin (2015-2020)
11.25.4 Verona Pharma Products Offered
11.25.5 Verona Pharma Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 PDE Inhibitors Market Estimates and Projections by Region
12.1.1 Global PDE Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global PDE Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America PDE Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: PDE Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: PDE Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: PDE Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe PDE Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: PDE Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: PDE Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: PDE Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific PDE Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: PDE Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: PDE Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: PDE Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America PDE Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: PDE Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: PDE Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: PDE Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa PDE Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: PDE Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: PDE Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: PDE Inhibitors Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key PDE Inhibitors Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 PDE Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. PDE Inhibitors Market Segments
Table 2. Ranking of Global Top PDE Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global PDE Inhibitors Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of PDE5
Table 5. Major Manufacturers of PDE4
Table 6. Major Manufacturers of Viagra
Table 7. Major Manufacturers of Cialis
Table 8. Major Manufacturers of Levitra
Table 9. Major Manufacturers of Others
Table 10. Global PDE Inhibitors Market Size Growth Rate by Application 2020-2026 (K Units)
Table 11. Global PDE Inhibitors Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 12. Global PDE Inhibitors Sales by Regions 2015-2020 (K Units)
Table 13. Global PDE Inhibitors Sales Market Share by Regions (2015-2020)
Table 14. Global PDE Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global PDE Inhibitors Sales by Manufacturers (2015-2020) (K Units)
Table 16. Global PDE Inhibitors Sales Share by Manufacturers (2015-2020)
Table 17. Global PDE Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global PDE Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PDE Inhibitors as of 2019)
Table 19. PDE Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. PDE Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers PDE Inhibitors Price (2015-2020) (USD/Unit)
Table 22. PDE Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers PDE Inhibitors Product Type
Table 24. Date of International Manufacturers Enter into PDE Inhibitors Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global PDE Inhibitors Sales by Type (2015-2020) (K Units)
Table 27. Global PDE Inhibitors Sales Share by Type (2015-2020)
Table 28. Global PDE Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 29. Global PDE Inhibitors Revenue Share by Type (2015-2020)
Table 30. PDE Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 31. Global PDE Inhibitors Sales by Application (2015-2020) (K Units)
Table 32. Global PDE Inhibitors Sales Share by Application (2015-2020)
Table 33. North America PDE Inhibitors Sales by Country (2015-2020) (K Units)
Table 34. North America PDE Inhibitors Sales Market Share by Country (2015-2020)
Table 35. North America PDE Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 36. North America PDE Inhibitors Revenue Market Share by Country (2015-2020)
Table 37. North America PDE Inhibitors Sales by Type (2015-2020) (K Units)
Table 38. North America PDE Inhibitors Sales Market Share by Type (2015-2020)
Table 39. North America PDE Inhibitors Sales by Application (2015-2020) (K Units)
Table 40. North America PDE Inhibitors Sales Market Share by Application (2015-2020)
Table 41. Europe PDE Inhibitors Sales by Country (2015-2020) (K Units)
Table 42. Europe PDE Inhibitors Sales Market Share by Country (2015-2020)
Table 43. Europe PDE Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe PDE Inhibitors Revenue Market Share by Country (2015-2020)
Table 45. Europe PDE Inhibitors Sales by Type (2015-2020) (K Units)
Table 46. Europe PDE Inhibitors Sales Market Share by Type (2015-2020)
Table 47. Europe PDE Inhibitors Sales by Application (2015-2020) (K Units)
Table 48. Europe PDE Inhibitors Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific PDE Inhibitors Sales by Region (2015-2020) (K Units)
Table 50. Asia Pacific PDE Inhibitors Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific PDE Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific PDE Inhibitors Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific PDE Inhibitors Sales by Type (2015-2020) (K Units)
Table 54. Asia Pacific PDE Inhibitors Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific PDE Inhibitors Sales by Application (2015-2020) (K Units)
Table 56. Asia Pacific PDE Inhibitors Sales Market Share by Application (2015-2020)
Table 57. Latin America PDE Inhibitors Sales by Country (2015-2020) (K Units)
Table 58. Latin America PDE Inhibitors Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa PDE Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America PDE Inhibitors Revenue Market Share by Country (2015-2020)
Table 61. Latin America PDE Inhibitors Sales by Type (2015-2020) (K Units)
Table 62. Latin America PDE Inhibitors Sales Market Share by Type (2015-2020)
Table 63. Latin America PDE Inhibitors Sales by Application (2015-2020) (K Units)
Table 64. Latin America PDE Inhibitors Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa PDE Inhibitors Sales by Country (2015-2020) (K Units)
Table 66. Middle East and Africa PDE Inhibitors Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa PDE Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa PDE Inhibitors Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa PDE Inhibitors Sales by Type (2015-2020) (K Units)
Table 70. Middle East and Africa PDE Inhibitors Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa PDE Inhibitors Sales by Application (2015-2020) (K Units)
Table 72. Middle East and Africa PDE Inhibitors Sales Market Share by Application (2015-2020)
Table 73. Hanmi Science Holding Corporation Information
Table 74. Hanmi Science Holding Description and Major Businesses
Table 75. Hanmi Science Holding PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 76. Hanmi Science Holding Product
Table 77. Hanmi Science Holding Recent Development
Table 78. Boehringer Ingelheim Corporation Information
Table 79. Boehringer Ingelheim Description and Major Businesses
Table 80. Boehringer Ingelheim PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 81. Boehringer Ingelheim Product
Table 82. Boehringer Ingelheim Recent Development
Table 83. Takeda Pharmaceuticals Corporation Information
Table 84. Takeda Pharmaceuticals Description and Major Businesses
Table 85. Takeda Pharmaceuticals PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 86. Takeda Pharmaceuticals Product
Table 87. Takeda Pharmaceuticals Recent Development
Table 88. AstraZeneca Corporation Information
Table 89. AstraZeneca Description and Major Businesses
Table 90. AstraZeneca PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 91. AstraZeneca Product
Table 92. AstraZeneca Recent Development
Table 93. Bayer Corporation Information
Table 94. Bayer Description and Major Businesses
Table 95. Bayer PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 96. Bayer Product
Table 97. Bayer Recent Development
Table 98. Celgene Corporation Information
Table 99. Celgene Description and Major Businesses
Table 100. Celgene PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 101. Celgene Product
Table 102. Celgene Recent Development
Table 103. Eli Lilly Corporation Information
Table 104. Eli Lilly Description and Major Businesses
Table 105. Eli Lilly PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 106. Eli Lilly Product
Table 107. Eli Lilly Recent Development
Table 108. Pfizer Corporation Information
Table 109. Pfizer Description and Major Businesses
Table 110. Pfizer PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 111. Pfizer Product
Table 112. Pfizer Recent Development
Table 113. BioCrea Corporation Information
Table 114. BioCrea Description and Major Businesses
Table 115. BioCrea PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 116. BioCrea Product
Table 117. BioCrea Recent Development
Table 118. Dart NeuroScience Corporation Information
Table 119. Dart NeuroScience Description and Major Businesses
Table 120. Dart NeuroScience PDE Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 121. Dart NeuroScience Product
Table 122. Dart NeuroScience Recent Development
Table 123. Carinopharm Corporation Information
Table 124. Carinopharm Description and Major Businesses
Table 125. Carinopharm PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 126. Carinopharm Product
Table 127. Carinopharm Recent Development
Table 128. CTC Bio Corporation Information
Table 129. CTC Bio Description and Major Businesses
Table 130. CTC Bio PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 131. CTC Bio Product
Table 132. CTC Bio Recent Development
Table 133. FORUM Pharmaceuticals Corporation Information
Table 134. FORUM Pharmaceuticals Description and Major Businesses
Table 135. FORUM Pharmaceuticals PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 136. FORUM Pharmaceuticals Product
Table 137. FORUM Pharmaceuticals Recent Development
Table 138. Intra-Cellular Therapies Corporation Information
Table 139. Intra-Cellular Therapies Description and Major Businesses
Table 140. Intra-Cellular Therapies PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 141. Intra-Cellular Therapies Product
Table 142. Intra-Cellular Therapies Recent Development
Table 143. Omeros Corporation Corporation Information
Table 144. Omeros Corporation Description and Major Businesses
Table 145. Omeros Corporation PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 146. Omeros Corporation Product
Table 147. Omeros Corporation Recent Development
Table 148. Medimetriks Pharmaceuticals Corporation Information
Table 149. Medimetriks Pharmaceuticals Description and Major Businesses
Table 150. Medimetriks Pharmaceuticals PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 151. Medimetriks Pharmaceuticals Product
Table 152. Medimetriks Pharmaceuticals Recent Development
Table 153. NuSirt Biopharma Corporation Information
Table 154. NuSirt Biopharma Description and Major Businesses
Table 155. NuSirt Biopharma PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 156. NuSirt Biopharma Product
Table 157. NuSirt Biopharma Recent Development
Table 158. Palobiopharma Corporation Information
Table 159. Palobiopharma Description and Major Businesses
Table 160. Palobiopharma PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 161. Palobiopharma Product
Table 162. Palobiopharma Recent Development
Table 163. Roivant Sciences Corporation Information
Table 164. Roivant Sciences Description and Major Businesses
Table 165. Roivant Sciences PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 166. Roivant Sciences Product
Table 167. Roivant Sciences Recent Development
Table 168. Sagene Pharmaceuticals Corporation Information
Table 169. Sagene Pharmaceuticals Description and Major Businesses
Table 170. Sagene Pharmaceuticals PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 171. Sagene Pharmaceuticals Product
Table 172. Sagene Pharmaceuticals Recent Development
Table 173. Tetra Discovery Partners Corporation Information
Table 174. Tetra Discovery Partners Description and Major Businesses
Table 175. Tetra Discovery Partners PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 176. Tetra Discovery Partners Product
Table 177. Tetra Discovery Partners Recent Development
Table 178. Tritech Biopharm Corporation Information
Table 179. Tritech Biopharm Description and Major Businesses
Table 180. Tritech Biopharm PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 181. Tritech Biopharm Product
Table 182. Tritech Biopharm Recent Development
Table 183. Otsuka Corporation Information
Table 184. Otsuka Description and Major Businesses
Table 185. Otsuka PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 186. Otsuka Product
Table 187. Otsuka Recent Development
Table 188. Chiesi Farmaceutici Corporation Information
Table 189. Chiesi Farmaceutici Description and Major Businesses
Table 190. Chiesi Farmaceutici PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 191. Chiesi Farmaceutici Product
Table 192. Chiesi Farmaceutici Recent Development
Table 193. Verona Pharma Corporation Information
Table 194. Verona Pharma Description and Major Businesses
Table 195. Verona Pharma PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 196. Verona Pharma Product
Table 197. Verona Pharma Recent Development
Table 198. Global PDE Inhibitors Sales Forecast by Regions (2021-2026) (K Units)
Table 199. Global PDE Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 200. Global PDE Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 201. Global PDE Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 202. North America: PDE Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 203. North America: PDE Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 204. Europe: PDE Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 205. Europe: PDE Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 206. Asia Pacific: PDE Inhibitors Sales Forecast by Region (2021-2026) (K Units)
Table 207. Asia Pacific: PDE Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 208. Latin America: PDE Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 209. Latin America: PDE Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 210. Middle East and Africa: PDE Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 211. Middle East and Africa: PDE Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 212. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 213. Key Challenges
Table 214. Market Risks
Table 215. Main Points Interviewed from Key PDE Inhibitors Players
Table 216. PDE Inhibitors Customers List
Table 217. PDE Inhibitors Distributors List
Table 218. Research Programs/Design for This Report
Table 219. Key Data Information from Secondary Sources
Table 220. Key Data Information from Primary Sources
List of Figures
Figure 1. PDE Inhibitors Product Picture
Figure 2. Global PDE Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. PDE5 Product Picture
Figure 4. PDE4 Product Picture
Figure 5. Viagra Product Picture
Figure 6. Cialis Product Picture
Figure 7. Levitra Product Picture
Figure 8. Others Product Picture
Figure 9. Global PDE Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 10. Genitourinary
Figure 11. Cardiovascular Diseases
Figure 12. Dermatological Disorders
Figure 13. Respiratory Diseases
Figure 14. Schizophrenia
Figure 15. Alzheimer’S Disease
Figure 16. Huntington’S Disease
Figure 17. Others
Figure 18. PDE Inhibitors Report Years Considered
Figure 19. Global PDE Inhibitors Market Size 2015-2026 (US$ Million)
Figure 20. Global PDE Inhibitors Sales 2015-2026 (K Units)
Figure 21. Global PDE Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 22. Global PDE Inhibitors Sales Market Share by Region (2015-2020)
Figure 23. Global PDE Inhibitors Sales Market Share by Region in 2019
Figure 24. Global PDE Inhibitors Revenue Market Share by Region (2015-2020)
Figure 25. Global PDE Inhibitors Revenue Market Share by Region in 2019
Figure 26. Global PDE Inhibitors Sales Share by Manufacturer in 2019
Figure 27. The Top 10 and 5 Players Market Share by PDE Inhibitors Revenue in 2019
Figure 28. PDE Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 29. Global PDE Inhibitors Sales Market Share by Type (2015-2020)
Figure 30. Global PDE Inhibitors Sales Market Share by Type in 2019
Figure 31. Global PDE Inhibitors Revenue Market Share by Type (2015-2020)
Figure 32. Global PDE Inhibitors Revenue Market Share by Type in 2019
Figure 33. Global PDE Inhibitors Market Share by Price Range (2015-2020)
Figure 34. Global PDE Inhibitors Sales Market Share by Application (2015-2020)
Figure 35. Global PDE Inhibitors Sales Market Share by Application in 2019
Figure 36. Global PDE Inhibitors Revenue Market Share by Application (2015-2020)
Figure 37. Global PDE Inhibitors Revenue Market Share by Application in 2019
Figure 38. North America PDE Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 39. North America PDE Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. North America PDE Inhibitors Sales Market Share by Country in 2019
Figure 41. North America PDE Inhibitors Revenue Market Share by Country in 2019
Figure 42. U.S. PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 43. U.S. PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. Canada PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 45. Canada PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. North America PDE Inhibitors Market Share by Type in 2019
Figure 47. North America PDE Inhibitors Market Share by Application in 2019
Figure 48. Europe PDE Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 49. Europe PDE Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 50. Europe PDE Inhibitors Sales Market Share by Country in 2019
Figure 51. Europe PDE Inhibitors Revenue Market Share by Country in 2019
Figure 52. Germany PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 53. Germany PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. France PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 55. France PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. U.K. PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 57. U.K. PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Italy PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 59. Italy PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Russia PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 61. Russia PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Europe PDE Inhibitors Market Share by Type in 2019
Figure 63. Europe PDE Inhibitors Market Share by Application in 2019
Figure 64. Asia Pacific PDE Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 65. Asia Pacific PDE Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 66. Asia Pacific PDE Inhibitors Sales Market Share by Region in 2019
Figure 67. Asia Pacific PDE Inhibitors Revenue Market Share by Region in 2019
Figure 68. China PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 69. China PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Japan PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 71. Japan PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. South Korea PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 73. South Korea PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. India PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 75. India PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Australia PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 77. Australia PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Taiwan PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 79. Taiwan PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Indonesia PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 81. Indonesia PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Thailand PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 83. Thailand PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Malaysia PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 85. Malaysia PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Philippines PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 87. Philippines PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Vietnam PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 89. Vietnam PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Asia Pacific PDE Inhibitors Market Share by Type in 2019
Figure 91. Asia Pacific PDE Inhibitors Market Share by Application in 2019
Figure 92. Latin America PDE Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 93. Latin America PDE Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 94. Latin America PDE Inhibitors Sales Market Share by Country in 2019
Figure 95. Latin America PDE Inhibitors Revenue Market Share by Country in 2019
Figure 96. Mexico PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 97. Mexico PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Brazil PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 99. Brazil PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Argentina PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 101. Argentina PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Latin America PDE Inhibitors Market Share by Type in 2019
Figure 103. Latin America PDE Inhibitors Market Share by Application in 2019
Figure 104. Middle East and Africa PDE Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 105. Middle East and Africa PDE Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 106. Middle East and Africa PDE Inhibitors Sales Market Share by Country in 2019
Figure 107. Middle East and Africa PDE Inhibitors Revenue Market Share by Country in 2019
Figure 108. Turkey PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 109. Turkey PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Saudi Arabia PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 111. Saudi Arabia PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 112. UAE PDE Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 113. UAE PDE Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 114. Middle East and Africa PDE Inhibitors Market Share by Type in 2019
Figure 115. Middle East and Africa PDE Inhibitors Market Share by Application in 2019
Figure 116. North America PDE Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. North America PDE Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Europe PDE Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 119. Europe PDE Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Asia Pacific PDE Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 121. Asia Pacific PDE Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Latin America PDE Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 123. Latin America PDE Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Middle East and Africa PDE Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 125. Middle East and Africa PDE Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Porter's Five Forces Analysis
Figure 127. Channels of Distribution
Figure 128. Distributors Profiles
Figure 129. Bottom-up and Top-down Approaches for This Report
Figure 130. Data Triangulation
Figure 131. Key Executives Interviewed